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Prospective evaluation of carotid bruit as a predictor of first stroke in
type II diabetes: The Fremantle Study
Gillett M, Davis WA, Paxon D, et al. Stroke 2003;34:2145-51.
Conclusion: After detection of a carotid bruit in a patient with type II
diabetes the risk for an initial stroke within 2 years is six times that in a patient
with type II diabetes without a carotid bruit.
Summary: The Fremantle Diabetes Study is an observational, prospec-
tive, community based study of diabetes in western Australia. Between 1993
and 1996, 1081 patients with type II diabetes and no history of cerebrovas-
cular disease were recruited and observed until the end of January 2002. Cox
proportional hazards models were used to identify significant cerebrovascu-
lar risk factors for stroke and to determine whether carotid bruit was an
independent predictor of first stroke in patients with type II diabetes.
After study entry, 134 patients (11.3%) developed a first stroke at a
mean of 6.5  2.2 years of follow-up. In the first 2 years after entering the
study, a first stroke occurred in 45 patients (3.8%). After adjustment for
cardiovascular risk factors and other potentially confounding variables, first
stroke in the first 2 years after study entry was strongly predicted by the
presence of carotid bruit (hazard ratio, 6.7; 95% confidence interval, 3.0-
14.9; P  .001). After 2 years of study observation, first stroke was not
associated with carotid bruit (P  .97). Both diastolic blood pressure and
age were also determinants of first stroke in the first 2 years after study entry.
Two years after study entry, age, atrial fibrillation or flutter, and microalbu-
minuria were independent predictors of stroke.
Comment: It might be concluded that patients with type II diabetes
and carotid bruit compose a subgroup who will derive benefit from prophy-
lactic carotid endarterectomy. However, the authors did not report the
degree of carotid stenosis in their patients, and it is not clear that all strokes
involved the extracranial cervical carotid artery. Clearly the data argue for
aggressive risk factor management in patients with type II diabetes and a
carotid bruit. The data, however, do not enable one to conclude that
patients with a carotid bruit and type II diabetes will benefit from prophy-
lactic carotid endarterectomy.
Carotid artery stenosis: Gray-scale and Doppler ultrasound diagnosis.
Society of Radiologists in Ultrasound Consensus Conference
Grant EG, Benson CB, Moneta GL, et al. Radiology 2003;229:340-6.
Conclusion: A consensus conference convened by the Society of
Radiologists in Ultrasound developed a set of criteria for grading internal
carotid artery (ICA) stenosis with Doppler ultrasound scanning. Criteria are
based primarily on ICA peak systolic velocity (PSV) and demonstration of
presence of plaque on gray-scale and color Doppler scans.
Summary: A multidisciplinary panel was charged to develop a set of
reasonable criteria for Doppler diagnosis of ICA stenosis. Criteria proposed
were based on review of the literature and presentations at the conference.
Recommendations included:
1. Use of gray-scale, color Doppler scanning and spectral Doppler ultra-
sound scanning for all carotid artery examinations
2. Stratification of ICA stenoses into six categories:
a. Normal: ICA PSV less than 125 cm/s, with no visible plaque or
intimal thickening
b. Less than 50% stenosis: ICA PSV less than 125 cm/s, with visible
plaque or intimal thickening
c. 50% to 69% stenosis: ICA PSV 125 to 230 cm/s, with visible plaque
d. ICA stenosis greater than 70% to near occlusion: ICA PSV greater
than 230 cm/s, with visible plaque and luminal narrowing on
gray-scale and color images
e. Near occlusion: color Doppler scan showing an extremely narrow
lumen
f. Total occlusion: no detectable lumen on gray-scale ultrasound scans
and no flow on color, power, or spectral Doppler scans
ICA–common carotid artery PSV ratio and ICA end-diastolic velocity
may also be used when it appears that ICA PSV may not represent the extent
of stenosis.
Comment: The conference consisted of panelists from radiology,
neurology, vascular surgery, vascular medicine, and interventional radiol-
ogy, among other specialties. Results represent what the panelists considered
to be reasonable criteria for ICA stenosis. It is suggested that these criteria be
considered by laboratories with insufficient angiographic material for vali-
dation of existing published criteria. The proposed criteria have not been
tested, and do not represent the results of any single publication. Laborato-
ries using published criteria validated locally are urged to continue to use
them.
Subcutaneous Fondaparinux vs intravenous unfractionated heparin in
initial treatment of pulmonary embolism
Matisse Investigators. N Engl J Med 2003;349:1695-1702.
Conclusion: Fondaparinux, given as once daily subcutaneous treat-
ment without monitoring, was as effective and as safe as intravenously
administered unfractionated heparin for treatment of hemodynamically
stable patients with symptomatic pulmonary embolism.
Summary: Fondaparinux is an antithrombotic synthetic agent with
specific anti–factor Xa; activity. It is administered as a single daily subcuta-
neous injection, and does not require monitoring of the anticoagulation
effect. This was an open-label trial of 2213 hemodynamically stable patients
with acute symptomatic pulmonary embolism. Pulmonary embolism was
diagnosed on the basis of findings of computed tomography, pulmonary
angiography, high-probability ventilation perfusion scanning, or a nondiag-
nostic lung scan with either duplex ultrasound scanning or venographic
diagnosis of deep venous thrombosis. Patients received either unfractionated
intravenous heparin via continuous infusion, with a target partial thrombo-
plastin time of one and a half to two and a half times control, or daily
subcutaneous Fondaparinux at a fixed weight-adjusted dose. Both drugs
were given for 5 days until oral anticoagulation therapy resulted in an
international normalized ratio greater than 2.0. The primary end point was
symptomatic recurrent pulmonary embolism or new or recurrent deep
venous thrombosis at 3 months.
New or recurrent pulmonary embolism or deep venous thrombosis
occurred in 42 of 1103 patients receiving Fondaparinux (3.8%) and in 56 of
1110 patients receiving unfractionated heparin (5.0%). Major bleeding
occurred in 1.1% of those given heparin and in 1.3% of those given Fondapa-
rinux. Mortality at 3 months was 5.2% in the Fondaparinux group, and 4.4%
in the heparin group. In the Fondaparinux group 14 patients died of
pulmonary embolism within 3 months, compared with 15 patients in the
heparin group.
Comment: The study demonstrates therapeutic equivalence of
Fondaparinux and continuous infusion of intravenous unfractionated hepa-
rin in the initial management of symptomatic pulmonary embolism in
hemodynamically stable patients. A single daily subcutaneous dose, com-
bined with no need for monitoring of the anticoagulant effect, makes
Fondaparinux an attractive alternative for initial management of uncompli-
cated pulmonary embolism.
Effective treatment of carotid artery stenosis on blood pressure: A
comparison of hemodynamic disturbances after carotid endarterec-
tomy in endovascular treatment
McKebitt FN, Sivaguru A, Venables GS, et al. Stroke 2003;34:2573-82.
Conclusion: Carotid endarterectomy and endovascular treatment of
carotid artery stenosis both affect blood pressure stability during the first 24
hours after the procedure. Compared with preoperative baseline levels,
systolic blood pressure at 6 months is lower in patients who undergo surgery,
and is unchanged in patients who undergo endovascular treatment.
Summary: Periprocedure and long-term blood pressure effects of
carotid endarterectomy and endovascular treatment of carotid artery steno-
sis were studied in patients randomized at a single center in the Carotid and
Vertebral Artery Transluminal Angioplasty Study (CAVATAS). Patients
were randomized to endovascular treatment of carotid stenosis (n  55) or
carotid endarterectomy (n  49). Ambulatory 24-hour blood pressure
monitoring was recorded before carotid intervention and at 24 hours, 1
month and 6 months after intervention. Hypotension and hypertension
were defined as a decrease or increase, respectively, in systolic blood pressure
of 30 mm Hg or greater from baseline blood pressure recordings.
After the procedure, in the first 24 hours hypotension occurred in 76%
of the endovascular group and 75% of the carotid endarterectomy group,
and hypertension occurred in 13% and 11%, respectively. At 1 hour systolic
blood pressure decreased by a mean of 24 mm Hg in the surgical group and
16 mm Hg in the endovascular group; however, the decrease was sustained
only in the endovascular group (P  .0001). At 6 months systolic pressure
was at baseline in the endovascular group, and was 5 mm Hg lower in the
surgical group. Thirty-day stroke and mortality rate was 10.2% in the surgical
group, and 5.5% in the endovascular group. Perioperative neurologic com-
plication was not related to perioperative hemodynamic disturbance.
Comment: The study suggests a difference in blood pressure response
after surgical versus endovascular therapy for carotid artery stenosis. In
surgical patients, however, a specific protocol was used to reverse hypoten-
sion, whereas no specific protocol was used in the stent group. The 6-month
data are difficult to interpret, because there is no follow-up information on
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number and dosage of antihypertensive medications in either group. This
study should be regarded as hypothesis-seeking, and does not definitively
establish a difference in blood pressure response after carotid endarterec-
tomy versus carotid stenting.
Cholesterol reduction with atorvastatin improves walking distance in
patients with peripheral arterial disease
Mohler ER, Hiatt WR, Creager MA, and Study Investigators. Circulation
2003;108:1481-6.
Conclusion: Atorvastatin improves pain-free walking distance as mea-
sured with treadmill testing in patients with intermittent claudication.
Summary: This was a randomized, double-blind, parallel-design study
of 354 patients with intermittent claudication secondary to peripheral
arterial disease. Patients were given either placebo, or 10 or 80 mg/d of
atorvastatin for 12 months, and evaluated in terms of treadmill exercise time,
ankle brachial index, self-reported measures of physical activity, and quality-
of-life questionnaires.
Atorvastatin did not change maximal treadmill walking time after 12
months of treatment. Pain-free walking time was improved with the 80-mg
dose of atorvastatin (P  .025) compared with placebo. There were no
differences in ankle-brachial index between the three groups at 12 months.
Twelve vascular events occurred during follow-up: 9 in the placebo group, 1
in the 10-mg atorvastatin group, and 2 in the 80-mg atorvastatin group.
Vascular events were higher in the placebo group than in the combined
Atorvastatin groups (P  0.003). Both the 80-mg and 10-mg atorvastatin
groups demonstrated improved physical activity compared with the placebo
group. There were no differences in quality of life as measured by the
short-form health survey (36 items) and Walking Impairment Question-
naire.
Comment: The heart protection study (Lancet 2002;360:7-22) dem-
onstrated a reduction in risk for death and adverse cardiac events in patients
with peripheral arterial disease without a previous cardiovascular event who
were treated with simvastatin. The current study also indicates that a statin,
atorvastatin, can improve pain-free walking distance and physical activity in
patients with intermittent claudication. Regardless of cholesterol level, it is
highly likely that all patients with symptomatic or asymptomatic atheroscle-
rosis will benefit from a statin medication.
Regional angiogenesis with vascular endothelial growth factor in pe-
ripheral arterial disease: A phase II randomized, double-blind, con-
trolled study of adenoviral delivery of vascular endothelial growth
factor 121 in patients with disabling intermittent claudication
Rajagopalan S, Mohler ER, Lederman RJ, et al. Circulation 2003;108:
1933-8.
Conclusion: A single set of intramuscular injections of adenoviral
vascular endothelial growth factor 121 (adVEGF121) did not result in
exercise improvement, increased ankle-brachial index, or improved quality
of life in patients with intermittent claudication.
Summary: Growth of new blood vessels to improve symptomatic
ischemia is termed therapeutic angiogenesis. This trial, the Regional Angio-
genesis with Vascular Endothelial Growth Factor (RAVE) trial was the first
major randomized study to evaluate the safety and efficacy of adVEGF121
gene transfer in treatment of peripheral vascular disease.
A replication-deficient adenovirus encoding the 121 amino acid iso-
form of VEGF was injected into the lower extremities of subjects with
unilateral peripheral arterial disease. The 105 patients were stratified on the
basis of diabetic status. All had unilateral exercise-limiting intermittent
claudication, and were randomized to either high-dose or low-dose ad-
VEGF121 therapy or placebo. Drug was given as 20 intramuscular injections
in the ipsilateral leg in a single session.
At 12 weeks there were no differences in change in peak walking time
among the placebo, low-dose, and high-dose groups. In addition, secondary
end points of ankle-brachial index, claudication onset time, and quality-of-
life assessment (short-form health survey [36 items] and Walking Impair-
ment Questionnaire) did not differ among the groups at 12 and 26 weeks.
No major safety issues were identified through 1 year of follow-up.
Comment: Several possible impairments to adenoviral transfection of
adult skeletal muscle may have contributed to the negative results of this
study. Possible impairments to transfection include muscle fascia, connective
tissue, and lower concentrations in skeletal muscle of the Coxsackie adeno-
viral receptor. Angiogenesis for treatment of peripheral arterial disease is still
more an interesting idea than practical reality.
Secondary prevention of venous thromboembolism with the oral direct
thrombin inhibitor Ximelagatran
Schulman S, Wahlander K, Lundstrom T, et al. N Engl J Med 2003;349:
1712-21.
Conclusion: Ximelagatran, an oral direct thrombin inhibitor, is supe-
rior to placebo in preventing recurrent venous thromboembolism, with no
increase in bleeding complications.
Summary: In a multicenter, double-blind trial, 1233 patients with
venous thromboembolism who had undergone 6 months of standard oral
anticoagulant therapy were randomly assigned to an additional 18 months of
treatment with either placebo or 24 mg twice daily of Ximelagatran. The
primary end point was recurrent venous thromboembolism. The two groups
were compared with respect to recurrent venous thromboembolism events
and hemorrhagic complications.
Of the 612 patients assigned to the Ximelagatran group, a primary end
point was reached in 12 patients. In the 611 patients assigned to the placebo
group, a primary end point was reached in 71 patients (hazard ratio, 0.16;
95% confidence interval, 0.09-0.30; P  .001).
There were six deaths in the Ximelagatran group, and seven deaths in
the placebo group. Bleeding occurred in 134 patients given Ximelagatran,
and in 111 control patients (hazard ratio, 1.19; 95% confidence interval,
0.93-1.53; P  .17). Major hemorrhage was infrequent, occurring in 6
patients in the Ximelagatran group and 5 patients in the placebo group.
There were three fatal pulmonary emboli in the placebo group, com-
pared with none in the Ximelagatran group. There was a cumulative risk for
transient elevation of alanine aminotransferase concentration to more than
three times normal in 6.4% of the Ximelagatran group and 1.2% of the
placebo group (P .001). Increase in aminotransferase levels was transient,
restricted to the first 4 months of therapy, and did not result in progressive
hepatic dysfunction. Levels decreased spontaneously whether or not Ximel-
agatran was continued.
Comment: Ximelagatran, unlike warfarin sodium, does not have any
clinically important known food or drug interactions. This drug, with an
overall safety profile comparable to that with placebo and no need for
laboratory monitoring, appears to be a low-risk, effective method for pre-
venting recurrent venous thromboembolism. Rat poison may once again be
relegated to rats.
Risk factors for death or stroke after carotid endarterectomy: Obser-
vations from the Ontario Carotid Endarterectomy Registry
Tu JV, Wang H, Bowyer B, et al, and participants in the Ontario Carotid
Endarterectomy Registry Stroke 2003;34:2568-75.
Conclusion: A history of transient ischemic attack or stroke, contralat-
eral occlusion, diabetes, atrial fibrillation, and congestive heart failure are
independent predictors for increased risk for stroke or death at 30 days after
carotid endarterectomy.
Summary: The study used data derived from the Ontario Carotid
Endarterectomy Registry, which contains information on all carotid endar-
terectomy procedures performed in Ontario, Canada, in calendar years 1994
to 1997. Medical records of all 6038 patients undergoing carotid endarter-
ectomy during this period were abstracted for patient characteristics and
30-day perioperative stroke and death. Data from 34 hospitals and 102
surgeons are represented in the study.
Overall 30-day stroke and death rate was 6.0%. Independent predictors
of 30-day stroke or death included history of transient ischemic attack or
stroke (odds ratio [OR], 1.75; 95% confidence interval [CI], 1.39-2.20),
contralateral carotid occlusion (OR, 1.72; 95% CI, 1.25-2.38), atrial fibril-
lation (OR, 1.89; 95% CI, 1.29-2.76), congestive heart failure (OR, 1.80;
95% CI, 1.15-2.81), and diabetes (OR, 1.28; 95% CI, 1.01-1.63). Assigning
1 point to each independent predictor, a total of 4 points was associated with
a 15.8% perioperative risk for stroke or death, whereas the absence of all of
the above independent predictors predicted a 3.3% perioperative risk for
stroke or death.
Comment: This report can help determine which of the growing
number of patients said to be at “high risk” are truly at high risk for
perioperative complication after carotid endarterectomy. Like all observa-
tional studies, this study is subject to selection bias, inasmuch as no infor-
mation is provided regarding patients who were considered for carotid
endarterectomy but did not undergo the procedure.
Future studies must concentrate, not only on identifying patients who
are at high risk for carotid intervention, but also on identifying patients who
are at particularly high risk for withholding intervention.
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